 The investigators previously identified a novel HLA-A0201-restricted epitope peptide, which was derived from a cancer-testis antigen, URLC10 as a target for vaccination against lung cancer. In this clinical study, the investigators examine using the peptides the safety, immunogenicity, and antitumor effect of vaccine treatment to prevent relapse of the disease for HLA-A0201-positive advanced non-small cell lung cancer patients whose disease are controlled after any standard therapies. 